Mоlimо vаs kоristitе оvај idеntifikаtоr zа citirаnjе ili оvај link dо оvе stаvkе:
https://open.uns.ac.rs/handle/123456789/2859
Nаziv: | Hydroxyurea and nonmelanoma skin cancers: Report on three cases and review of the literature | Аutоri: | Roš, Tatjana Gajić, Branislava Gajinov, Zorica Ivkov Simić, Milana Stojanović , Marko Golušin, Zoran |
Dаtum izdаvаnjа: | 1-нов-2017 | Čаsоpis: | Vojnosanitetski Pregled | Sažetak: | © 2017, Institut za Vojnomedicinske Naucne Informacije/Documentaciju. All rights reserved. Introduction. Hydroxyurea (HU) is a cytostatic agent, frequently used for the treatment of myeloproliferative disorders, sickle cell anemia and severe forms of psoriasis. Cutaneous side effects occur in up to one third of patients taking hydroxyurea, with the most serious side effect being susceptibility to develop non-melanoma skin cancers. Case report. We report 3 patients using HU that have developed multiple skin malignancies on the head and neck region and dorsa of the hands, arranged according to the level of the overall squamous dysplasia expressed. Conclusion. A cumulative dose of hydroxyurea affects skin cancer promotion in concordance with other risk factors determining cumulative ultraviolet exposure (age of the patients, skin phototype, sun habits), but the exact influence of each of them and enrollment of other possible cofactors remains to be elucidated. We point out the importance of adequate skin cancer preventive and therapeutic approach to the patients treated with hydroxyurea. | URI: | https://open.uns.ac.rs/handle/123456789/2859 | ISSN: | 428450 | DOI: | 10.2298/VSP160218298R |
Nаlаzi sе u kоlеkciјаmа: | MDF Publikacije/Publications |
Prikаzаti cеlоkupаn zаpis stаvki
SCOPUSTM
Nаvоđеnjа
1
prоvеrеnо 03.05.2024.
Prеglеd/i stаnicа
46
Prоtеklа nеdеljа
14
14
Prоtеkli mеsеc
8
8
prоvеrеnо 10.05.2024.
Google ScholarTM
Prоvеritе
Аlt mеtrikа
Stаvkе nа DSpace-u su zаštićеnе аutоrskim prаvimа, sа svim prаvimа zаdržаnim, оsim аkо nije drugačije naznačeno.